Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant sintilimab + ipilimumab in resectable stage II–IIIB (N2) NSCLC without pCR after neoadjuvant therapy
ChiCTR2600122947Phase 4Not yet recruiting
- Sponsor
- Sir Run-Run Shaw Hospital
- Start
- Apr 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of sintilimab and ipilimumab in non-small cell lung cancer (NSCLC), sponsored by Sir Run-Run Shaw Hospital. Primary endpoint: 2-year disease-free survival rate. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
sintilimabipilimumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2600122947.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600122947.